| Post-trial access to antiretrovirals: who owes what to whom? | |
| | |
MedLine Citation:
|
PMID: 19594728 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Many recent articles argue that participants who seroconvert during HIV prevention trials deserve treatment when they develop AIDS, and there is a general consensus that the participants in HIV/AIDS treatment trials should have continuing post-trial access. As a result, the primary concern of many ethicists and activists has shifted from justifying an obligation to treat trial participants, to working out mechanisms through which treatment could be provided. In this paper I argue that this shift frequently conceals an important assumption: that if there is an obligation to supply treatment, then any party who could provide it may be prevailed upon to discharge the obligation. This assumption is false. The reasons why trial participants should get ART affect who has the duty to provide it. We should not burden governments with the obligations of sponsors, nor researchers with the obligations of the international community. And we should not deprive a group of treatment because their need is less salient than that of research participants. Insisting otherwise may lead to people being wrongfully deprived of access to antiretrovirals. |
| | |
Authors:
|
Joseph Millum |
Related Documents
:
|
14751708 - Scaling-up treatment for hiv/aids: lessons learned from multidrug-resistant tuberculosis. 2216558 - Amenorrhea, osteopenia, and the female athlete. 2085158 - Endodontic file design and dynamics in automated root canal preparation. concepts, mate... 7632548 - Nocturnal enuresis. 536968 - Screening for hypertension: some practical problems. 8285078 - Mental accounting and the process of multiattribute choice. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Bioethics Volume: 25 ISSN: 1467-8519 ISO Abbreviation: Bioethics Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-02-02 Completed Date: 2011-06-08 Revised Date: 2012-03-08 |
Medline Journal Info:
|
Nlm Unique ID: 8704792 Medline TA: Bioethics Country: England |
Other Details:
|
Languages: eng Pagination: 145-54 Citation Subset: E; IM |
Copyright Information:
|
© 2009 Blackwell Publishing Ltd. |
Affiliation:
|
Clinical Center Department of Bioethics/Fogarty International Center, Building 10, Room 1C118, NIH Clinical Center, National Institutes of Health, Bethesda, MD 20892, USA. millumj@cc.nih.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Retroviral Agents
/
therapeutic use* Bioethical Issues Clinical Trials as Topic / ethics* HIV Infections / drug therapy*, prevention & control* Health Services Accessibility / ethics* Humans Research Subjects* |
| Grant Support | |
ID/Acronym/Agency:
|
Z99 CL999999/CL/CLC NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Retroviral Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Human dignity in international policy documents: a useful criterion for public policy?
Next Document: Mercury Exposure Increases Circulating Net Matrix Metalloproteinase (MMP)-2 and MMP-9 Activities.